Stereospecific analysis of omeprazole supports artemisinin as a potent inducer of CYP2C19

Fundamental and Clinical Pharmacology

Volumn 13, Issue 6, 1999, Pages 671-675

  Mihara, Kazuo ^a   Svensson, Ulrika S H ^b   Tybring, Gunnel ^a   Hai, Trinh Ngoc ^c   Bertilsson, Leif ^a   Ashton, Michael ^b  

^a KAROLINSKA INSTITUTE   (Sweden)

^b UPPSALA UNIVERSITY   (Sweden)

^c Pharmaceutical Unit   (Viet Nam)

Author keywords

Artemisinin; CYP2C19; Enantiomers; Induction; Metabolism; Omeprazole

Indexed keywords

5 HYDROXYOMEPRAZOLE; ANTIMALARIAL AGENT; ARTEMISININ; CYTOCHROME P450; OMEPRAZOLE; OMEPRAZOLE DERIVATIVE; UNCLASSIFIED DRUG;

AREA UNDER THE CURVE; ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG METABOLISM; DRUG RESEARCH; ENANTIOMER; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NORMAL HUMAN; PRIORITY JOURNAL; STEREOSPECIFICITY;

EID: 0033427677     PISSN: 07673981     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1472-8206.1999.tb00379.x     Document Type: Article

References (13)

1. [1] Ashton M., Sy N.D., Gordi T., Hai T.N., Thach D.C., Huong N.V., Farah M.H., Johansson M., Công L.D., Evidence for time-dependent artemisinin kinetics in adults with uncomplicated malaria, Pharm. Pharmacol. Lett. 6 (1996) 127-130.
2. [2] Ashton M., Hai T.N., Sy N.D., Huong D.X., Huong N.V., Niêu N.T., Công L.D., Artemisinin pharmacokinetics is time-dependent during repeated oral administration in healthy male adults, Drug Metab. Dispos. 26 (1998) 25-27.
3. [3] Ashton M., Gordi T., Trinh N.H., Nguyen V.H., Nguyen D.S., Nguyen T.N., Dinh X.H., Johansson M., Công L.D., Artemisinin pharmacokinetics in healthy adults after 250, 500 and 1000 mg single oral doses, Biopharm. Drug Dispos. 19 (1998) 245-250.
4. [4] Svensson U.S.H., Ashton M., Hai T.N., Bertilsson L., Huong D.X., Huong N.V., Niêu N.T., Sy N.D., Lykkesfeldt J., Công L.D., Artemisinin induces omeprazole metabolism in human beings, Clin. Pharmacol. Ther. 64 (1998) 160-167.
5. [5] Andersson T., Miners J.O., Veronese M.E., Birkett D.J., Identification of human liver cytochrome P450 isoforms mediating secondary omeprazole metabolism, Br. J. Clin. Pharmacol. 37 (1994) 597-604.
6. [6] Böttiger Y., Tybring G., Götharson E., Bertilsson L., Inhibition of the sulphoxidation of omeprazole by ketoconazole in poor and extensive metabolizers of S-mephenytoin, Clin. Pharmacol. Ther. 62 (1997) 384-391.
7. [7] Tybring G., Böttiger Y., Widén J., Bertilsson L., Enantioseleclive hydroxylation of omeprazole catalysed by CYP2C19 in Swedish white subjects, Clin. Pharmacol. Ther. 62 (1997) 129-137.
8. [8] Houston J.B., Drug Metabolite Kinetics, Pharmacol. Ther. 15 (1982) 521-552.
9. [9] Chang M., Dahl M.-L., Tybring G., Götharson E., Bertilsson L., Use of omeprazole as a probe drug for CYP2C19 phenotype in Swedish caucasians: comparison with S-mephenytoin hydroxylation phenotype and CYP2C19 genotype, Pharmacogenetics 5 (1995) 358-363.
10. [10] Roh H.K., Dahl M.L., Tybring G., Yamada H., Cha Y.N., Bertilsson L., CYP2C19 genotype and phenotype determined by omeprazole in a Korean population, Pharmacogenetics 6 (1996) 547-551.
11. [11] Svensson U.S.H., Sandström R., Carlborg Ö., Lennernäs H., Ashton M., High in situ rat intestinal permeability of artemisinin unaffected by multiple dosing and with no evidence of P-glyco-protein involvement, Drug Metab. Dispos. 27 (1999) 227-232.
12. [12] Watkins P.B., Wrighton S.A., Schuetz E.G., Molowa D.T., Guzelian P.S., Identification of glucocorticoid-inducible cytochromes P-450 in the intestinal mucosa of rats and man, J. Clin. Invest. 80 (1987) 1029-1036.
13. [13] Ashton M., Sy N.D., Huong N.V., Gordi T., Hai T.N., Huong D.X., Niêu N.T., Công L.D., Artemisinin kinetics and dynamics during oral and rectal treatment of uncomplicated malaria, Clin. Pharmacol. Ther. 63 (1998) 482-493.